{"entity":{"id":"lomond-therapeutics","kind":"company","name":"Lomond Therapeutics","aka":["Lomond Therapeutics Holdings, Inc."],"tldr":"Lomond Therapeutics is developing two tablets for blood cancers: lomonitinib, which blocks the FLT3 and IRAK4 proteins in acute myeloid leukaemia, and lonitoclax, which blocks BCL-2 in chronic lymphocytic leukaemia and acute myeloid leukaemia. Both are in early trials.","summary":"Lomond Therapeutics Holdings, Inc. is a Delaware biopharmaceutical company focused on haematological cancers. According to its 2025 annual report on Form 10-K (filed April 2026), it was co-founded by OrbiMed Advisors, Torrey Pines Investment and Dr John C. Byrd, was spun out of Eilean Therapeutics, LLC (its former parent), and became an SEC registrant through a reverse merger with Venetian-1 Acquisition Corp. on 1 November 2024; its common stock was not listed on an exchange or quoted over the counter, and it filed a Form 15 on 10 July 2026 to terminate its registration. Its lead candidate lomonitinib (ZE46-0134) is an oral inhibitor of FLT3, including resistance mutations, and IRAK4, in a phase 1 dose escalation and expansion study in FLT3-mutated or spliceosome-mutated relapsed or refractory AML (NCT06366789). It holds an exclusive worldwide licence from Eil Therapeutics to lonitoclax (ZE50-0134), a BCL-2 inhibitor tested in healthy volunteers (NCT06787131), in relapsed or refractory B-cell cancers including CLL and small lymphocytic lymphoma (NCT06708897) and with azacitidine in AML (NCT07303660); a menin inhibitor licence from Bala Therapeutics was terminated in early 2026. Its first registered cancer trial, NCT06366789, was posted on ClinicalTrials.gov in April 2024.","asOf":"2026-10-29","links":[{"label":"SEC EDGAR filings for Lomond Therapeutics Holdings (CIK 0001900520)","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001900520"},{"label":"Form 10-K for 2025, filed 15 April 2026","url":"https://www.sec.gov/Archives/edgar/data/1900520/000121390026044136/ea0283646-10k_lomond.htm"},{"label":"ClinicalTrials.gov: phase 1 trial of lomonitinib (ZE46-0134) in relapsed or refractory AML (NCT06366789)","url":"https://clinicaltrials.gov/study/NCT06366789"},{"label":"ClinicalTrials.gov: phase 1 trial of lonitoclax in relapsed or refractory B-cell cancers (NCT06708897)","url":"https://clinicaltrials.gov/study/NCT06708897"},{"label":"ClinicalTrials.gov: phase 1b trial of lonitoclax with azacitidine in AML (NCT07303660)","url":"https://clinicaltrials.gov/study/NCT07303660"}],"tags":[],"related":[],"cancers":["aml","cll","mds"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors","bcl2-inhibitors"],"targets":["flt3","bcl2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No company website was found: the domains lomondtherapeutics.com and lomondtx.com did not resolve on 29 October 2026, and the registry contact domains point to Eilean Therapeutics (eileanther.com), the former parent. Facts come from SEC EDGAR filings for CIK 0001900520 (10-K filed 15 April 2026; Form 15-12G filed 10 July 2026), read on 29 October 2026.","The Dover, Delaware address is the principal executive office given in the filings, which appears to be a registered-office address; where staff work was not confirmed.","Financing was by private placements, convertible preferred stock, a promissory note from Eilean and SAFEs according to the 10-K; round sizes were not read, so no funding rows are listed. Founding year not stated in the passages read.","No drug records exist in OnCo for lomonitinib or lonitoclax."],"hq":"Dover, DE","country":"US","companyType":"biotech","stage":"startup","investors":["orbimed"],"funding":[]},"route":"/companies/lomond-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"company":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"}]}}